References
- Benjamin, D. J., Berger, J. O., Johannesson, M., Nosek, B. A., Wagenmakers, E. J., Berk, R., Bollen, K. A., Brembs, B., Brown, L., Camerer, C., and Cesarini, D. (2018), “Redefine Statistical Significance,” Nature Human Behaviour, 2, 6. DOI:10.1038/s41562-017-0189-z.
- Browne, R. H. (2010), “The t-Test p Value and Its Relationship to the Effect Size and P(X>Y) ,” The American Statistician, 64, 30–33. DOI:10.1198/tast.2010.08261.
- Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., and Wang, S. (2009) “Dabigatran Versus Warfarin in Patients With Atrial Fibrillation,” New England Journal of Medicine, 361, 1139–1151. [Erratum, N Engl J Med 2010;363:1877.] DOI:10.1056/NEJMoa0905561.
- Ionnidis, J. P. A. (2005), “Why Most Published Research Findings Are False,” PLoS Medicine, 2, e124.
- Keefe, R. S. E., Kraemer, H. C., Epstein, R. S., Frank, E., Haynes, G., Laughren, T. P., and Leon, A. C. (2013), “Defining a Clinically Meaningful Effect for the Design and Interpretation of Randomized Controlled Trials,” Innovations in Clinical Neuroscience, 10, 4S–19S.
- Lesaffre, E. (2008), “Superiority, Equivalence, and Non-inferiority Trials,” Bulletin of the NYU Hospital for Joint Diseases, 66, 150–154.
- Rosnow, R. L., and Rosenthal, R. (2003), “Effect Sizes for Experimenting Psychologists,” Canadian Journal of Experimental Psychology, 57, 221–237. DOI:10.1037/h0087427.
- Wasserstein, R. L., and Lazar, N. A. (2016), “The ASA’s Statement on p-Values: Context, Process and Purpose,” The American Statistician, 70, 129–133. DOI:10.1080/00031305.2016.1154108.